Seneca Biopharma, Inc., (NASDAQ: SNCA) is a clinical-stage biopharmaceutical company developing novel treatments for diseases of unmet medical need. Seneca is in the process of finding and acquiring new assets, promising sciences and technologies that will provide meaningful therapies for patients.
The Company’s legacy technology platform enables the generation and commercial-scale production of regionally specific neural stem cell lines for use in therapeutic indications or drug screening and high content screening of compound libraries for discovery of novel CNS-targeted compounds.
The Company is currently in the process of identifying and acquiring new technologies and new assets.
During the spring of 2019 the company announced the initiation of a program to expand its current pipeline of therapeutic products. Seneca Bio is focused on the continued development of its current technologies and has also engaged a network of trusted experts and advisors to assist us in evaluating new technologies. This initiative has identified certain preclinical and clinical stage assets that we believe, if developed, could create significant value for shareholders while expanding and diversifying our product pipeline.View Our Pipeline